Request for Free Sample

Table of Content

1. Introduction

1.1 Market Definition

1.2 Scope (Inclusion and Exclusions)

1.3 Research Assumptions

2. Executive Summary

2.1 Market Overview

2.2 Regional Synopsis

2.3 Competitive Summary

3. Research Methodology

3.1 Top-Down Approach

3.2 Bottom-up Approach

3.3. Data Validation

3.4 Primary Interviews

4. Market Dynamics Impact Analysis

4.1 Market Driving Factors Analysis

4.1.2 Drivers

4.1.2 Restraints

4.1.3 Opportunities

4.1.4 Challenges

4.2 PESTLE Analysis

4.3 Porter’s Five Forces Model

5. Statistical Insights and Trends Reporting

5.1 Incidence and Prevalence Trends (2023)

5.2 Prescription Trends by Region (2023)

5.3 Drug Volume: Production & Usage Volumes (2023)

5.4 Healthcare Spending on HIV Therapeutics (2023)

6. Competitive Landscape

6.1 List of Major Companies, By Region

6.2 Market Share Analysis, By Region

6.3 Product Benchmarking

6.3.1 Product specifications and features

6.3.2 Pricing

6.4 Strategic Initiatives

6.4.1 Marketing and promotional activities

6.4.2 Distribution and supply chain strategies

6.4.3 Expansion plans and new product launches

6.4.4 Strategic partnerships and collaborations

6.5 Technological Advancements

6.6 Market Positioning and Branding

7. Human Immunodeficiency Virus Therapeutics Market Segmentation, By Drug Type

7.1 Chapter Overview

7.2 Branded Drugs

7.2.1 Branded Drugs Market Trends Analysis (2021-2032)

7.2.2 Branded Drugs Market Size Estimates and Forecasts to 2032 (USD Billion)

7.3 Generic Drugs

7.3.1 Generic Drugs Market Trends Analysis (2021-2032)

7.3.2 Generic Drugs Market Size Estimates and Forecasts to 2032 (USD Billion)

8. Human Immunodeficiency Virus Therapeutics Market Segmentation, By Drug Class

8.1 Chapter Overview

8.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)

8.2.1 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Market Trends Analysis (2021-2032)

8.2.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Market Size Estimates and Forecasts to 2032 (USD Billion)

8.3 Protease Inhibitors (PIs)

8.3.1 Protease Inhibitors (PIs) Market Trends Analysis (2021-2032)

8.3.2 Protease Inhibitors (PIs) Market Size Estimates and Forecasts to 2032 (USD Billion)

8.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

8.4.1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Market Trends Analysis (2021-2032)

8.4.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Market Size Estimates and Forecasts to 2032 (USD Billion)

8.5 Integrase Inhibitors

8.5.1 Integrase Inhibitors Market Trends Analysis (2021-2032)

8.5.2 Integrase Inhibitors Market Size Estimates and Forecasts to 2032 (USD Billion)

8.6 Entry and Fusion Inhibitors

8.6.1 Entry and Fusion Inhibitors Market Trends Analysis (2021-2032)

8.6.2 Entry and Fusion Inhibitors Market Size Estimates and Forecasts to 2032 (USD Billion)

8.7 Coreceptor Antagonists

8.7.1 Coreceptor Antagonists Market Trends Analysis (2021-2032)

8.7.2 Coreceptor Antagonists Market Size Estimates and Forecasts to 2032 (USD Billion)

9. Regional Analysis

     9.1 Chapter Overview

     9.2 North America

9.2.1 Trends Analysis

9.2.2 North America Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)

9.2.3 North America Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion) 

9.2.4 North America Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.2.5 USA

9.2.5.1 USA Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.2.5.2 USA Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.2.6 Canada

9.2.6.1 Canada Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.2.6.2 Canada Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.2.7 Mexico

9.2.7.1 Mexico Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.2.7.2 Mexico Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.3 Europe

9.3.1 Trends Analysis

9.3.2 Europe Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)

9.3.3 Europe Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion) 

9.3.4 Europe Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.3.5 Germany

9.3.5.1 Germany Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.3.5.2 Germany Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.3.6 France

9.3.6.1 France Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.3.6.2 France Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.3.7 UK

9.3.7.1 UK Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.3.7.2 UK Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.3.8 Italy

9.3.8.1 Italy Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.3.8.2 Italy Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.3.9 Spain

9.3.9.1 Spain Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.3.9.2 Spain Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.3.10 Poland

9.3.10.1 Poland Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.3.10.2 Poland Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.3.11 Turkey

9.3.11.1 Turkey Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.3.11.2 Turkey Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.3.12 Rest of Europe

9.3.12.1 Rest of Europe Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.3.12.2 Rest of Europe Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.4 Asia Pacific

9.4.1 Trends Analysis

9.4.2 Asia Pacific Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)

9.4.3 Asia Pacific Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion) 

9.4.4 Asia Pacific Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.4.5 China

9.4.5.1 China Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.4.5.2 China Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.4.6 India

9.4.5.1 India Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.4.5.2 India Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.4.5 Japan

9.4.5.1 Japan Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.4.5.2 Japan Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.4.6 South Korea

9.4.6.1 South Korea Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.4.6.2 South Korea Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.4.7 Singapore

9.4.7.1 Singapore Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.4.7.2 Singapore Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

8.4.8 Australia

8.4.8.1 Australia Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

8.4.8.2 Australia Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.4.9 Rest of Asia Pacific

9.4.9.1 Rest of Asia Pacific Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.4.9.2 Rest of Asia Pacific Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.5 Middle East & Africa

9.5.1 Trends Analysis

9.5.2 Middle East & Africa Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)

9.5.3 Middle East & Africa Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion) 

9.5.4 Middle East & Africa Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.5.5 UAE

9.5.5.1 UAE Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.5.5.2 UAE Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.5.6 Saudi Arabia

9.5.6.1 Saudi Arabia Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.5.6.2 Saudi Arabia Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.5.7 Qatar

9.5.7.1 Qatar Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.5.7.2 Qatar Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.5.8 South Africa

9.5.8.1 South Africa Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.5.8.2 South Africa Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.5.9 Middle East & Africa

9.5.9.1 Middle East & Africa Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.5.9.2 Middle East & Africa Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.6 Latin America

9.6.1 Trends Analysis

9.6.2 Latin America Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)

9.6.3 Latin America Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion) 

9.6.4 Latin America Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.6.5 Brazil

9.6.5.1 Brazil Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.6.5.2 Brazil Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.6.6 Argentina

9.6.6.1 Argentina Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.6.6.2 Argentina Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

9.6.7 Rest of Latin America

9.6.7.1 Rest of Latin America Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Type (2021-2032) (USD Billion)

9.6.7.2 Rest of Latin America Human Immunodeficiency Virus Therapeutics Market Estimates and Forecasts, By Drug Class Industry (2021-2032) (USD Billion)

10. Company Profiles

10.1 AbbVie Inc.

10.1.1 Company Overview

10.1.2 Financial

10.1.3 Products/ Services Offered

110.1.4 SWOT Analysis

10.2 Cipla

10.2.1 Company Overview

10.2.2 Financial

10.2.3 Products/ Services Offered

10.2.4 SWOT Analysis

10.3 Boehringer Ingelheim International GmbH

10.3.1 Company Overview

10.3.2 Financial

10.3.3 Products/ Services Offered

10.3.4 SWOT Analysis

10.4 Dr. Reddy's Laboratories

10.4.1 Company Overview

10.4.2 Financial

10.4.3 Products/ Services Offered

10.4.4 SWOT Analysis

10.5 Bristol-Myers Squibb Company

10.5.1 Company Overview

10.5.2 Financial

10.5.3 Products/ Services Offered

10.5.4 SWOT Analysis

10.6 Genentech, Inc.

10.6.1 Company Overview

10.6.2 Financial

10.6.3 Products/ Services Offered

10.6.4 SWOT Analysis

10.7 Gilead Sciences, Inc.

10.7.1 Company Overview

10.7.2 Financial

10.7.3 Products/ Services Offered

10.7.4 SWOT Analysis

10.8 Merck & Co., Inc.

10.8.1 Company Overview

10.8.2 Financial

10.8.3 Products/ Services Offered

10.8.4 SWOT Analysis

10.9 ViiV Healthcare

10.9.1 Company Overview

10.9.2 Financial

10.9.3 Products/ Services Offered

10.9.4 SWOT Analysis

10.10 Aurobindo Pharma

             10.9.1 Company Overview

10.9.2 Financial

10.9.3 Products/ Services Offered

10.9.4 SWOT Analysis

11. Use Cases and Best Practices

12. Conclusion